The influence of finasteride on the development of prostate cancer

Article Abstract:

The drug finasteride may reduce the risk of prostate cancer but if prostate cancer does develop, it is more likely to be serious. This was the conclusion of a study of 9,060 men, in which finasteride lowered the risk of developing prostate cancer by about 25% compared to a placebo. However, the men who took finasteride and still developed prostate cancer were more likely to have a serious form of cancer. They also experienced sexual problems caused by the drug.

Author: Lippman, Scott M., Goodman, Phyllis J., Coltman, Charles A., Jr., Crowley, John J., Ford, Leslie G., Atkins, James N., Lieber, Michael M., Thompson, Ian M., Tangen, Catherine M., Lucia, M. Scott, Miller, Gary J., Cespedes, R. Duane, Carlin, Susie M., Ryan, Anne, Szczepanek, Connie M.
Evaluation, Development and progression, Finasteride

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


level <= 4.0 ng per milliliter

Article Abstract:

A study was conducted, in the prostate cancer prevention trial, to investigate the prevalence of prostate cancer among men who had a prostate-specific antigen (PSA) level of 4.0 ng per milliliter or less. The result shows the percentage of prevalence of prostate cancer among men, and reveals that the biopsy-detected prostate cancer is not rare among men with PSA levels of 4.0 ng per milliliter or less.

Author: Lippman, Scott M., Crawford, E. David, Goodman, Phyllis J., Crowley, John J., Ford, Leslie G., Lucia, M. Scott, Thompson, Ian M, Pauler, Donna K, Tangen, Catherine M, Parnes, Howard L., Minasian, Lori M., Coltman, Charles A., Jr
HEALTH SERVICES, Cancer Therapy, Ambulatory Health Care Services, Cancer treatment

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower

Article Abstract:

A study is conducted to estimate the receiver operating characteristic curve for prostate-specific antigen (PSA). It is concluded that there is no cutpoint of PSA with simultaneous high sensitivity and high specificity for monitoring healthy men for prostate cancer, but rather a continuum of prostate cancer risk at all values of PSA.

Author: Goodman, Phyllis J., Coltman, Charles A., Jr., Crowley, John J., Parnes, Howard L., Thomspon, Ian M., Chen Chi; Lucia, M. Scott, Ankerst, Donna Pauler
United States, Risk factors, Men

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Prevention, Prostate cancer, Research, Men's health, Prostate-specific antigen, Prostate specific antigen
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.